Form 4 for CRL Charles River Laboratories
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001127602-25-002799 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-03 | 2025-01-31 | CRL | Pease Flavia | CFO, Corp. Executive VP | A - Grant | $0.00 | +2,704 | 12.5K | +28% | $0 | |
| 2025-02-03 | 2025-01-31 | CRL | Pease Flavia | CFO, Corp. Executive VP | F - Tax | $165.57 | -914 | 11.6K | -7% | -$151.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | A | A | 2,704 | $0.00 | 12,464 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022. |
| 2 | Common | Common Stock | 2025-01-31 | F | D | 914 | $165.57 | 11,550 | D | — | — |